ABBV News and Press, AbbVie Inc.

2026-02-28 10:05:04 ET More on market Fed Rate Cuts On Hold, But Liquidity Conditions Still Look Supportive For Stocks They Said Stocks Would Only Return 6%, They Were Wrong Follow Rates Of Change To Be Ahead Of The Curve In 2026 UBS cuts US equities to bench...

2026-02-27 12:21:05 ET 2026 Review The Dividend Aristocrats are enjoying an excellent beginning to 2026. The ProShares S&P 500 Dividend Aristocrat ETF ( NOBL ) was up 5.67% in January, and with one more trading day left in February, it is set to lock in a second consecutive ...

2026-02-26 13:35:52 ET More on leading drugmakers Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade) Merck: Why Investors Should Remain Bullish Despite Patent Risks ...

2026-02-26 07:30:11 ET MRK and ABBV stocks’ FQ4 earnings I last covered AbbVie Inc. ( ABBV )( ABBV:CA ) on Jan 8, 2026, with an article titled “AbbVie: The Dividend Does Not Lie”. The article was triggered by ABBV’s dividend declaration made f...

2026-02-25 16:13:07 ET More on Enveric Biosciences Enveric Biosciences announces $1.5M registered direct offering, warrant placement; shares down Seeking Alpha’s Quant Rating on Enveric Biosciences Financial information for Enveric Biosciences Read t...

2026-02-25 11:59:52 ET More on AbbVie AbbVie: Dominating Immunology While Building Oncology Upside AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript AbbVie: The Market Is Getting It Wrong AbbVie earmarks $38...

2026-02-25 10:03:10 ET Shares of skin disease concern Oruka Therapeutics, Inc. ( ORKA ) have more than doubled since its IL-23p19 antagonist ORKA-001 demonstrated a half-life four times greater than Skyrizi in a Phase 1 study. The once or twice-yearly psoriasis candidate is undergoi...

2026-02-24 18:03:48 ET Trung Huynh from RBC Capital issued a price target of $260.00 for ABBV on 2026-02-24 21:07:00. The adjusted price target was set to $260.00. At the time of the announcement, ABBV was trading at $228.44. The overall price target consensus is at $255...

2026-02-24 13:50:12 ET The last time I wrote an article on MoonLake Immunotherapeutics ( MLTX ), it was in a Seeking Alpha article entitled " MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest. " At that time, things were looking very good for th...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, Baystreet.ca News Commentary , The global oncology and cancer drugs market, valued at $167 billion in 2023, is projected to reach $335.2 billion by 2033 at a compound annual growth rate of 7.2% [1] . Forecasts for the broader oncolog...